A collaboration between Nuclea Biotechnologies, Inc. (MA, USA) and Thermo Fisher Scientific (MA, USA) is enabling their scientists to pool expertise to develop novel multiplexed research methods for high-throughput quantification of native insulin and its therapeutic analogs. The levels of these markers can be monitored, which may be useful in predicting responses to therapy for Type 2 diabetes.
Nuclea has extensive experience in developing and commercializing biomarkers and clinical tests. While the Thermo Fisher Scientific Biomarker Research Initiatives in Mass Spectrometry (BRIMS) Center has successfully worked with with numerous leading clinical researchers, to apply MS to biomarker discovery and its translation to high-throughput, quantitative methods.
The collaborating scientists from Nuclea and the BRIMS Center will develop multiplexed MS-based research methods, which Nuclea will use to analyze donor plasma samples from Boston-based diabetes research collaborations.
The collaborative work will use a proprietary platform that combines Thermo Scientific MSIA immuno-enrichment technology, TSQ Vantage or Quantiva triple quadrupole mass spectrometers and Pinpoint Software.
Nuclea and the BRIMS Center have previously successfully combined forces, as described by Nuclea Chief Executive Officer, Patrick Muraca: “We’ve already worked with the BRIMS Center to develop two other very important assays. These assays have demonstrated the sensitivity, precision and robustness needed for high-throughput detection of clinically relevant isoforms of target proteins.”
“The real-world application of multiplexed MS-based methods to Type 2 diabetes presents an opportunity to advance research in this crucial area” explained Mary Lopez, director of the BRIMS Center, Thermo Fisher Scientific. “Nuclea’s proven ability to validate and develop routine assays means our collaboration can support research efforts.”